PFS | OS | |||||
---|---|---|---|---|---|---|
Hazard ratio | 95% CI | P | Hazard ratio | 95% CI | P | |
Baseline CTC status (CTC BL ) | ||||||
< 5 CTC (CTCBL-) | 1.00 | 1.00 | ||||
≥ 5 CTC (CTCBL+) | 1.55 | 1.19–2.01 | 0.001 | 2.79 | 2.04–5.63 | < 0.001 |
Age at inclusion | ||||||
Per year | 0.99 | 0.98–1.00 | 0.207 | 1.00 | 0.99–1.01 | 0.938 |
Number of metastatic sites | ||||||
One site | 1.00 | 1.00 | ||||
Multiple sites | 0.97 | 0.66–1.43 | 0.892 | 0.71 | 0.41–1.23 | 0.227 |
Site of metastasis | ||||||
Bone | 1.00 | 1.00 | ||||
Visceral/local | 0.98 | 0.67–1.46 | 0.939 | 1.75 | 1.00–3.01 | 0.052 |
Both | 1.07 | 0.71–1.63 | 0.739 | 2.55 | 1.41–4.60 | 0.002 |
Line of therapy | ||||||
1 | 1.00 | 1.00 | ||||
2 | 1.35 | 0.93–1.95 | 0.113 | 1.45 | 0.92–2.28 | 0.112 |
≥ 3 | 1.91 | 1.40–2.59 | < 0.001 | 2.01 | 1.37–2.96 | < 0.001 |
Molecular Subtypes | ||||||
HR+/HER2- | 1.00 | ° | 1.00 | |||
HER2+ | 1.10 | 0.79–1.52 | 0.577 | 1.09 | 0.72–1.63 | 0.695 |
TNBC | 1.92 | 1.36–2.71 | < 0.001 | 2.86 | 1.91–4.27 | < 0.001 |